Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Lung Cancer. 2007 Jul 3;58(1):95–103. doi: 10.1016/j.lungcan.2007.05.017

Table 3.

Overall responses in the 99 EGFR-mutant evaluated patients

Patient population Source (reference) CR+PR (%) SD (%) PD (%) Total
Chemotherapy naïve (1st line therapy) Inoue (43) 12 (75%) 2 (12.5%) 2 (12.5%) 16
Asahina (44) 12 (75%) 1 (6%) 3 (19%) 16
Mixed 1st and subsequent lines of therapy Sutani (45) 21 (78%) 5 (18.5%) 1 (3.5%) 27
Yoshida (46) 19 (90.5%) 1 (4.8%) 1 (4.8%) 21
Sunaga (47) 16 (84%) 3 (15%) 0 (0%) 19*
Total 80 (80.8%) 12 (12.1%) 7 (7.1%) 99

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease

*

in the prospective trial by Sunaga et al. (47) 21 patients were entered, however 2 discontinued treatment and only 19 were available for analysis of overall response to gefitinib therapy